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Histologic assessment of kidney transplant biopsies relies on cortex rather than medulla, but 
for microarray studies, the proportion cortex in a biopsy is typically unknown and could affect the 
molecular readings. The present study aimed to develop a molecular estimate of proportion cortex in 
biopsies and examine its effect on molecular diagnoses.  Microarrays from 26 kidney transplant 
biopsies divided into cortex and medulla components and processed separately showed that many of 
the most significant differences were in glomerular genes e.g. NPHS2, NPHS1, CLIC5, PTPRO, 
PLA2R1, PLCE1, PODXL and REN.  Using NPHS2 (podocin) to estimate proportion cortex, we 
examined whether proportion cortex influenced molecular assessment in the Molecular Microscope 
Diagnostic System. In 1190 unselected kidney transplant indication biopsies 
(Clinicaltrials.govNCT01299168), only 11% had <50% cortex. Molecular scores for ABMR, TCMR,  
and injury were independent of proportion cortex. Rejection was diagnosed in many biopsies that were 
mostly or all medulla.  Agreement in molecular diagnoses in paired cortex/medulla samples (23/26) 
was similar to biological replicates (32/37). We conclude that NPHS2 expression can estimate 
proportion cortex; that proportion cortex has little influence on molecular diagnosis of rejection, and 
that, although histology cannot assess medulla, rejection does occur in medulla as well as cortex.  
Abstract 
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 Limitations in existing diagnostic methods have triggered a strong interest in molecular 
phenotyping of kidney transplant biopsies as a new dimension in disease understanding. We recently 
developed a system for translating gene expression measurements into diagnostic assessment, the 
Molecular Microscope Diagnostic system (MMDx) (1). Like histology, molecular biopsy assessment 
system requires consideration of the effect of sample adequacy. For example, when histologically 
assessing kidney transplant biopsies an adequate specimen must have at least 10 glomeruli and two 
arteries (2), usually requiring at least two cores. These features and the proportion of cortex in the 
biopsy core are not known when using molecular phenotyping. The biopsies we have processed to 
date, acquired in consented studies under institutional review board approval, have usually been 
relatively small segments of single biopsy cores (mean 3mm), and stabilized immediately to prevent 
mRNA degradation without assessing the proportion of cortex.  
Introduction  
 The present study was initiated to learn the effect of the proportion cortex on the fidelity of 
molecular readings, and whether rejection and injury can be assessed molecularly in medulla. This 
required us to develop a system for estimating proportion of cortex in a core, and to use this estimate 
to measure the relationship between proportion of cortex and molecular readings. We obtained a set 
of kidney transplant biopsies that were divided by a nephrologist (GAB) into cortex and medulla pieces 
before stabilization, based on visual assessment (light microscopy) of the presence of glomeruli as the 
indicator of cortex and medullary rays as the indicator of medulla. Our goal was to define the top 
transcripts distinguishing cortex from medulla, develop a molecular estimate of the proportion of 
cortex, and incorporate this knowledge into MMDx molecular diagnostic reports. We then looked at the 
relationship between estimated proportion of cortex and various molecular scores that we had 
previously published including T cell-mediated rejection (TCMR) (3), antibody-mediated rejection 
(ABMR) (4;5), all rejection (ABMR, TCMR, or mixed rejection) (6), and acute kidney injury (AKI) (7). To 
facilitate interpretation of MMDx readings on paired cortex-medulla samples, we also studied the 
reproducibility of MMDx readings in technical and biological replicates. 
These biopsies were collected in the INTERCOMEX study Clinicaltrials.gov NCT01299168. 
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Biopsy collection and processing 
Materials and Methods 
The cortex-medulla comparison cohort included 26 renal allograft needle biopsies (two partial 
cores each), three unpaired cortex and one medulla samples from 26 recipients, performed for graft 
dysfunction and/or proteinuria within the INTERCOMEX study (www.clinicaltrials.gov, NCT01299168) 
between June and October 2015. Biopsies were provided within budgetary constraints and per 
project/ethics protocols for submission to the INTERCOMEX study. Specimens were selected if they 
contained sufficient material for a comprehensive evaluation of both conventional morphology and 
region-specific molecular gene expression patterns. Biopsies were performed under ultrasound 
guidance using a 16 or 18 gauge needle. Immediately after biopsy, one core was evaluated by 
microscopy; the approximate number of glomeruli was determined in 15 biopsies. This core was 
separate from those sent for routine assessment (histology, immunochemistry and electron 
microscopy). The core was divided into two pieces (1-3 mm length), designated cortex and medulla by 
its morphological appearance including the presence of one or more glomeruli (median 2.5 glomeruli 
per cortical specimen, interquartile range (IQR) 2.25-3, range 1-10) versus medulla showing the 
presence of medullary rays without glomeruli. Immediately after counting the number of glomeruli, 
specimens for molecular workup were suspended in RNAlater® and were immediately shipped at 
room temperature. 
Paired cortex/medulla sample processing included RNA extraction and microarray analysis on 
Affymetrix GeneChip® arrays. Purified total RNA was labeled with the 3' IVT Plus kit (Affymetrix, 
Santa Clara) and hybridized to PrimeView microarrays (Affymetrix) according to manufacturer 
protocols published at www.affymetrix.com. Microarray data was preprocessed by Robust Multiarray 
Average.  
Resulting .CEL files were processed in R, and an automated report was generated. 
Processing time from extraction to reporting was ~48 hours. Reports for paired cortex and medulla 
biopsies were signed out simultaneously, and the classifier scores and gene expression 
measurements compared. Completed reports with a sign-out and comments were returned to the 
participating center.  
Biopsies divided in half without assessing proportion cortex for use as biological replicates 
were at least 4mm in length, and were selected initially based on size and diagnosis from the samples 
in the study. The biopsy core was then cut evenly in half, and both halves were processed separately  
as ‘B1” and “B2”.  Reports and sample quality data were generated for both samples, and molecular 
scores compared and documented.  
Technical replicates (Figure 1) were prepared by dividing the RNA extracted from a single 
biopsy into two aliquots and processing the aliquots in parallel by two technicians. Reports and sample 
quality data were produced for both samples.  
The “.CEL” files will be uploaded to Gene Expression Omnibus. 
 
Histology assessments of biopsies. 
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Histologic evaluation was done on formalin-fixed paraffin-embedded sections. For C4d 
staining, a polyclonal anti-C4d antibody (BI-RC4D, Biomedica, Vienna, Austria) was used. Rejection 
features were graded and scored according to the Banff 2013.  
 
Developing a molecular estimate of proportion cortex 
Proportion cortex was molecularly determined using expression of the glomerular podocyte-
specific transcript NPHS2 (podocin). NPHS2 is expressed exclusively in glomerulus and thus cortex, 
and is not known to be regulated in disease states.  Thus NPHS2 expression is directly correlated to 
the proportion of cortex in a sample. A logistic regression equation was calculated based on samples 
submitted and microscopically determined to be either medulla or cortex, and used to calculate 
proportion of cortex in unknown samples. Since our main goal was to identify samples with little or no 
cortex, cutoffs for proportion cortex were chosen arbitrarily as 0.2 in some experiments. 
 
MMDx assessment 
 The output from the microarray is expressed in terms of 30 different classifiers and gene set 
scores and interpreted by a single observer (PFH) on the basis of the molecular classifier and gene 
set scores, without considering the conventional phenotype (histology, HLA antibody) (1). Thus the 
results, like histology, are not based on any one result but on a combination of results.  
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The methods for creating technical replicate pairs, biological replicate pairs, and cores divided 
into cortex and medulla for separate processing are shown in Figure 1. Technical replicates were two 
microarrays performed on separate aliquots from the same RNA sample; biological replicates were 
two microarrays performed on halves of one biopsy core processed in parallel with no visual 
assessment of proportion cortex in the original core.  
Results 
Demographics for the biological replicates, and cortex – medulla divided pairs, and the kidney 
biopsy reference set (N=1208) are shown in Table 1. All biopsies were for clinical indications, 
including investigation of newly discovered DSA. Routine protocol biopsies in patients with low risk 
were not included. The demographics of the 37 biopsies chosen for division into two halves as 
biological replicates and the 26 biopsies selected for division into cortex and medulla are also shown 
in Table 1.  
 
Gene expression differences between cortex and medulla 
We compared gene expression between paired cortex and medulla samples, expressed 
(Figure 2) as fold change (y axis) in cortex vs. medulla, vs. the p value based on a paired t-test 
comparing cortex and medulla samples, in 26 cortex-medulla pairs (x axis). The probe sets most 
differentially expressed are labeled.  
Table 2 ranks the top 30 differentially expressed probe sets by p value. All of the top 30 had 
higher expression in cortex, as did 339 of the 408 probesets (83%) that differed between cortex and 
medulla with false discovery rate (FDR) <0.0001.  Thus no medulla-selective genes were among the 
top 30.  
NPHS2/podocin was the most differentially expressed gene, both by p value (FDR = 6.2 x 10-
7
 
) and fold change (average 28.6-fold higher in the cortex samples compared to the medulla samples). 
For this reason, we selected NPHS2 expression as the basis for estimating the proportion of cortex in 
biopsy samples. NPHS2 expression is restricted to the cortex, in particular to the glomerular podocyte, 
and is relatively stable in its expression (8). NPHS2 is shown in Figure 3 to define cortexness in an 
histologically determined cortex or medulla sample as well as the other 29 of the top 30 probe sets in 
a principal components analysis.  
 
Developing an estimate of proportion of cortex using NPHS2 
We studied the expression of NPHS2 in samples divided and separately processed as cortex 
or medulla (Figure 4A). Samples designated medulla had much lower NPHS2 expression than cortex 
samples.  
To establish an equation estimating the proportion of cortex in a biopsy, we assumed that the 
divided samples were either cortex or medulla as labeled. We also included four biopsies that during 
preparation of the divided cortex-medulla cores were found by light microscopy to be either all cortex 
(N=3) and all medulla (N=1). 
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The distribution of predicted proportion based on NPHS2 expression is shown in Figure 4B. 
The predicted proportion of cortex (and NPHS2 expression) was high in most cortex samples and low 
in most medulla samples. 
 We analyzed the distribution of NPHS2 expression in the reference set of 1190 intact biopsies 
(i.e. not divided into cortex and medulla). Figure 5 shows the density plot distribution of NPHS2 
expression, compared to the actual cortex (top) and medulla (bottom) samples used to generate the 
measurement. A large proportion (89%) of the reference set biopsies had higher than 50% proportion 
cortex and overlapped the cortex samples. A small proportion of biopsies had low expression of 
NPHS2.  
 
Effect of proportion of cortex estimates on the reference set MMDx readings 
The distribution in molecular scores across the high cortex and low cortex samples was 
compared to establish if the molecular ABMR, TCMR, and rejection scores were affected by predicted 
proportion cortex in a sample (y axis in Figure 6). The biological replicates, the cortex/medulla pairs, 
and the reference set minus cortex-medulla samples are shown separately.  
Positive ABMR molecular scores (right of the dotted vertical line, cutoff =0.2) were found in 
samples with both high and low proportion cortex (above and below dotted horizontal line, 
respectively, cutoff =0.2).  No significant difference in ABMR scores was found in the biological 
replicates, the cortex/medulla subset, or the reference set minus cortex-medulla samples, respectively 
i.e. the likelihood of a positive molecular score was not consistently different in samples with high or 
low cortex content (Figure 6A, 6B, 6C). The results for the molecular TCMR scores (Figure 6D, 6E, 
and 6F) and rejection scores (Figure 6G, 6H, and 6I) were similar. The statistical results from Chi 
square tests for these data are shown in Table 3. 
Similar analyses were performed to determine if a relationship existed between the scores of 
the AKI transcripts (IRRAT scores). Figure 7 shows the distributions of the predicted proportion cortex 
(y-axis) vs. the AKI score. There was no relationship between the predicted proportion of cortex and 
molecular AKI (IRRAT scores). The statistical results from Chi square tests for Figure 7 are shown in 
Table 3. 
 
Effect of proportion cortex on the molecular rejection and injury scores  
In an independent approach, we compared the difference in four molecular scores (TCMR, 
ABMR, rejection, and AKI transcripts (IRRATs)) between cortex and medulla to the difference seen 
between technical replicates or biological replicates. (The cortex and medulla segments were usually 
smaller than the other cores used for assessment, potentially increasing the sampling error.) The 
difference in the molecular scores for TCMR, ABMR, all rejection, and IRRAT in the technical 
replicates (upper panels), biological replicates (middle panels), and cortex-medulla pairs (lower 
panels) is shown in Figure 8.  
The difference between the two scores can be seen on the y axis versus the mean of the two 
scores (x axis). The difference in the molecular TCMR, ABMR, and rejection scores between technical 
replicates was minimal (Figure 8, upper panels), and the difference between biological replicates 
(Figure 8, middle panels) was similar to that between technical replicates. The difference between 
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cortex and medulla segments of a divided core (Figure 8, lower panels) was greater than in the 
biological replicates. However, the positive-negative classifier calls for TCMR, ABMR, or rejection 
(indicated by the horizontal line) were usually in agreement.  
 
MMDx assessment of cortex-medulla pairs and biological replicate pairs by multiple classifiers  
Diagnostic assessment of the microarray analysis of a biopsy in the MMDx system uses 
multiple classifier scores for each rejection diagnosis and is interpreted by a single observer (PFH) 
independent of the histology and DSA status (1) as outlined in Materials and Methods and in a 
forthcoming paper (Halloran et al. Real time central assessment of kidney transplant indication 
biopsies by microarrays: The INTERCOMEX Study. Manuscript submitted 2017).  The diagnoses 
considered for this analysis were ABMR and TCMR.  The consistency of diagnoses in paired samples 
of cortex and medulla was compared to the biological replicate set (Table 4). The data were divided 
into three groups based on their molecular report diagnostic sign-out: agreement; agreement with a 
difference in scale i.e. ‘severe TCMR’ vs. ‘moderate TCMR’); and disagreement.  
Agreement between paired samples for the cortex-medulla set (23/26, 88%) was similar to the 
agreement between paired samples in the biological replicate set (32/37, 86%). These agreement 
values correlated more closely than the interobserver agreement usually recorded for histology 
assessments (15;16). 
 
The present study addressed the question of whether molecular methods could assess the 
proportion of cortex in a biopsy core and how the relative proportions of cortex versus medulla in a 
biopsy core would affect the molecular diagnosis of rejection and injury using the MMDx system. We 
identified genes whose expression was different in cortex and medulla and then used the top example, 
NPHS2/podocin, as a marker to determine the proportion of each biopsy that was cortex vs. medulla, 
and the effect of proportion cortex in 1190 biopsies on their interpretation in the MMDx system.  In a 
smaller subset of paired biopsies, we directly compared the MMDx signatures between cortex and 
medulla from the same biopsy in technical replicates, biological replicates, and cortex-medulla pairs. 
The conclusion from both these data sets was that MMDx signatures were not impacted in a major 
way by whether the sample was largely medulla or largely cortex, although 89% of samples were 
>50% cortex.  Cortex and medulla samples are less concordant than either biological or technical 
replicates but this generally did not affect the interpretation. This is important because sample 
collection for tissue RNA analysis usually specifies that the sample be immediately placed into RNA 
preservative without estimating the proportion cortex in order to avoid compromising RNA integrity. 
Thus when assessing kidney transplant biopsies using microarrays we are able to estimate the 
proportion cortex in each biopsy and to read rejection and injury information even when the biopsy is 
largely medulla. Finally, in a qualitative sense, MMDx finds that medulla does undergo typical rejection 
processes, which are currently not being assessed by the histology diagnostic system that does not 
enable diagnoses of rejection in medulla. This suggests that molecular methods will be able to read 
other tissues that are currently not assessable by the current histology guidelines such as bronchial 
mucosa of lung transplants, and that all donor tissue probably undergoes rejection and injury. 
Discussion 
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We conclude that molecular changes of rejection and injury and can be assessed in medulla 
and show general agreement with cortex of the same specimen. Furthermore, we conclude that the 
molecular scores vary more between cortex and medulla than expected from biological replicates but 
this generally will not affect disease interpretation by the classifiers and molecular scores.  We note, 
however, that there are certain limitations to these conclusions, due to the small number of samples 
with certain combinations of features, e.g. samples with TCMR that also have a low proportion cortex. 
The potential for type II error limits the strength of inferences that can be drawn from the statistical 
findings, though additional studies will follow as more samples become available. 
The use of NPHS2/podocin mRNA to estimate proportion of cortex for each biopsy sample is 
supported by current knowledge of NPHS2/podocin biology, which along with the data presented here 
indicates that very low NPHS2/podocin mRNA is mainly due to high medulla content. There are three 
reasons why a transplant kidney biopsy sample might have low expression of NPHS2: (i) the sample 
is comprised largely of medulla (containing no glomeruli); (ii) the expression of NPHS2 is depressed 
by injury and/or inflammation; and (iii) many glomeruli are sclerotic and may have lost NPHS2 mRNA 
(17). Biopsies with TCMR had moderately reduced NHPS2 mRNA (by about 50%) but not to the very 
low levels characteristic of medulla (28-fold lower than cortex). We also reviewed NPHS2/podocin 
mRNA in our previous mouse kidney transplant microarray studies, and found that TCMR and AKI 
reduced expression of NPHS2 by a maximum of 50-70% (data not shown), similar to the reductions in 
other transcripts characteristic of well differentiated kidney tissue (13;14). In addition, we studied our 
data on human biopsies with extensive atrophy-fibrosis (histologic ci scores >1) to see if they had lost 
NPHS2, and found relatively little loss compared to kidney transplants with little atrophy-fibrosis (ci<1), 
supporting the utility of NPHS2 as a guide to low proportion cortex even in the presence of atrophy-
fibrosis.  
Podocyte loss does occur in glomerular sclerosis and in glomerular inflammation/injury such 
as in transplant glomerulopathy or recurrent glomerular disease (18), but the loss of NPHS2 mRNA 
may be partially offset by compensatory hypertrophy and increased expression in the remaining 
glomeruli.  
The use of gene expression to reflect proportion of cortex versus medulla is not dependent on 
the assumption that gene expression will not change in disease states, but only that the genes specific 
for cortex are relatively well preserved in disease states. Many genes identified as preferentially 
expressed in cortex are well-known to be central to glomerular function because (a) their mutations 
are associated with inherited glomerular diseases including diffuse mesangial sclerosis, congenital 
nephrotic syndrome and focal and segmental glomerulosclerosis (NPHS1, NPHS2, PTPRO, PLCE1) 
(8); (b) circulating antibodies directed against the protein are associated with glomerular disease, 
namely membranous nephropathy (PLA2R1) (9); (c) they are key to renin-angiotensin system 
regulation through the juxta-glomerular apparatus (REN, renin) (10); or (d) they have otherwise been 
identified as highly expressed by glomerular podocytes (CLIC5, PODXL) (11;12). Tubulo-interstitial 
processes such as AKI or TCMR may cause some reduction in expression of the genes typical of the 
functioning kidney but not complete loss (13;19). Thus for the purposes of identifying samples that are 
primarily medulla, very low NPHS2/podocin is reliable, but we should remain cognizant of potential 
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disease-related loss of expression of NPHS2 or other cortex genes when diffuse inflammatory 
diseases such as TCMR are operating.  
Note that some samples labeled as medulla had high expression of NPHS2 and some labeled 
cortex had relatively low expression.  This is not unexpected given the small size of the samples and 
the imperfect separation between cortex and medulla, where the precise boundary is difficult to 
establish by visual inspection using light microscopy.  
Two features emerged for the TCMR score in relationship to proportion of cortex estimates. 
First, there were very few high TCMR scores in samples with the highest proportion cortex (0.9-1.0), 
suggesting that TCMR may somewhat reduce NPHS2 expression, as it does with other kidney 
transcripts as shown in mouse kidney allografts with TCMR (13;14). Nevertheless the majority of 
TCMR was in samples with proportion cortex estimates of 0.5-0.9, indicating that any reduction of 
NPHS2 expression due to TCMR or other diseases did not approach the very low levels observed in 
medulla. Second, although high TCMR scores are often recorded in samples with very low cortex 
content (i.e. medulla), there were fewer positive TCMR scores in Reference Set samples with very low 
proportion cortex, although the p value (0.03) was of only borderline significance. We therefore cannot 
exclude the possibility that TCMR is underrepresented in samples with very low proportion of cortex.  
While the proportion of cortex has no major effect on the performance of the molecular scores, 
the difference between cortex and medulla pairs was greater than between technical or biological 
replicates (within the limits of the power of this sample size of 1208 biopsies) inviting a caveat when 
diagnosing rejection molecularly in pure medulla. The number of biopsies in the reference set with 
almost pure medulla samples as estimated by NPHS2 expression was small: less than 10% of 
biopsies had <0.5 estimated proportion of cortex, and fewer still had less 10% cortex.  In the future as 
we develop new classifiers to estimate rejection, the effect of proportion cortex can be tested for each 
and possibly included as a variable in the algorithm.  
Based on this analysis, molecular AKI changes (as estimated by the IRRAT score) are similar 
in cortex and medulla. IRRAT molecular scores were distributed similarly in the cortex-medulla set, the 
biological replicates set, and the reference set. We previously reported (in an earlier version of the 
reference set) that assessment of injury should be molecular because this correlates with function 
whereas histologic estimates of acute tubular injury do not (7). We now add that AKI can be 
molecularly detected in medulla.  This is not surprising, given that the top genes expressed in acutely 
injured kidneys are often expressed in other injured tissues and in cancers, reflecting the tendency of 
tissues to lose their differentiated features and become more similar after injury. For example, we find 
that many AKI transcripts are also increased in biopsies from injured heart transplants (unpublished 
observations).  
While these studies give reassurance about the reliability of molecular assessment on the 
biopsies available for the studies, the ideal biopsy size for molecular interpretation cannot be 
estimated because of the limited cores available for this research study. The average biopsy was only 
3 mm in length i.e. a fraction of one core, far below the amount of tissue used for histology 
assessment. As molecular studies become routine and cores of greater length are available, the 
relationship between biopsy size and stability of the molecular scores should continue to be explored, 
particularly for TCMR, which is sometimes patchy in histologic assessment. Nevertheless the ability of 
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the MMDx system to assess small tissue samples is an advantage over histology, provided that 
histologic assessment of glomerular diseases (e.g. recurrent glomerulonephritis) is not required. 
Having said that, the expression of mRNA for a number of important glomerular transcripts in the 
microarray readout raises the possibility that conclusions about glomerular diseases may eventually 
be inferred directly from core biopsies without micro dissecting the glomeruli. 
In conclusion, NPHS2 can be used to estimate proportion cortex for MMDx purposes. NPHS2 
is subject to small loss of expression in disease but the cortex-medulla differences override these. 
Rejection and injury do occur in medulla and can be read molecularly, and the proportion cortex does 
not seem to have a major influence on the ability to read rejection and injury.  
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Figure Legends 
Figure 1.
 
 Diagram showing the sampling strategy for the technical replicate pairs, biological replicate 
pairs, and cortex-medulla pairs.  
Figure 2.
 
 Volcano plot of fold change between cortex and medulla vs. negative log of adjusted p value 
with false discovery rate. NPHS2 had the highest association and fold change between cortex and 
medulla of 55,000 probe sets. A selection of highly significant probe sets distinguishing cortex from 
medulla is labeled.  
Figure 3.
 
 Predicted proportion of cortex in a sample histologically called cortex or medulla using either 
the principal component 1 score based on 29 of the top 30 probe sets (excluding NPHS2) (y-axis) or 
using NPHS2 expression alone (x-axis). 
Figure 4.
 
 Boxplot showing log of NPHS2 expression in medulla and cortex samples as established by 
histology (A) and the predicted proportion cortex distribution across all samples (B). Box shows the 
interquartile range, horizontal bar - median and whiskers - 1.5 X standard deviation. 
Figure 5.
 
 Density plot of NPHS2 expression in 1190 non-bisected biopsy cores. Black symbols show 
the distribution of NPHS2 expression values in cortex and medulla divided pair samples, respectively.  
Figure 6.
 
 Scatter plots with predicted proportion cortex (y axis) vs. molecular ABMR, TCMR, and 
rejection scores in the biological replicate set, the cortex and medulla set, and the reference set (x 
axis. Vertical dotted line indicates the positive/negative cutoffs for the molecular scores; horizontal 
dotted line indicates the 0.2/0.8 split for the proportion of cortex. ABMR, antibody-mediated rejection; 
TCMR, T cell-mediated rejection. 
Figure 7.
 
 Investigating the relationship between injury (IRRAT score) and proportion of cortex. Vertical 
dotted line indicates the arbitrary positive/negative cutoff for the molecular IRRAT scores; horizontal 
dotted line indicates an arbitrary 0.2/0.8 split for the proportion of cortex. IRRAT, acute kidney injury 
transcripts. 
Figure 8.
 
 Reproducibility plots of the molecular scores of rejection (TCMR, ABMR, all rejection) and 
acute kidney injury (IRRAT) in the technical and biological replicates and in the cortex-medulla divided 
pairs. Dotted horizontal line indicates the positive/negative cutoffs for the molecular scores. The y 
axes are the scores for the two samples compared for the TCMR, ABMR, and Rejection classifiers (a 
number between 0 and 1.0) or the geometric mean of the expression of the AKI transcripts (IRRATs). 
The x axis is the mean of classifier or IRRAT scores. ABMR, antibody-mediated rejection; AKI, acute 
kidney injury; IRRAT, acute kidney injury transcripts; TCMR, T cell-mediated rejection. 
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Table 1. Demographics of the patients and the biopsy sets 
 
Biological replicates 
(N=37 pairs) 
Cortex vs. Medulla 
(N=26 pairs + 4 unpaired 
from 26 recipients) 
Reference set 
(N=1208) 
Patient characteristics 
Mean recipient age (years) 52 (22-77) (1 NA) 53 (29-71) 50 (9 - 91) 
Recipient Gender (% male) 69% (2 NA) 58% 53% 
Primary Disease  
    Diabetic nephropathy 7 2 180 
    Glomerulonephritis/vasculitis 5 5 47 
    Interstitial nephritis/pyelonephritis 5 4 25 
    Polycystic kidney disease 2 3 120 
    Others 10 3 788 
    Unknown etiology/blank 8 9 48 
Mean donor age (years) 45 (10 NA) 54 43  
Donor gender (% male) 55% (8 NA) 65% (3 NA) 48% (347 NA or 
blank) 
Donor type (% deceased donor transplant) 65% 77% 65% 
 Biopsy characteristics       
Median and mean time from transplant to biopsy  1959 (905) days 944 (62) days 592 (1553) days 
Range 26.2 years 17.1 years 31.4 years 
    Primary non-function 2 8 10 
    Rapid deterioration of function 8 2 211 
    Slow deterioration of function 5 9 217 
    Stable impaired graft function 0 0 79 
    Investigate proteinuria 4 3 185 Au
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    Follow-up from previous biopsy 5 3 91 
    Others 13 5 415 
Conventional biopsy diagnosis   
   
ABMR 12 10 215 
ABMR suspicious 0 4 24 
AKI 0 14 96 
Borderline 1 2 109 
Interstitial fibrosis and tubular atrophy (IFTA) 4 6 145 
Normal/NOMOA  (No major abnormalities, No rejection) 6 14 274 
TCMR 3 2 87 
Mixed 1 2 41 
Other or N/A 10 2 217 
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Table 2. Top 30 probe sets regarding fold change between cortex and medulla using a paired t-test 
P Value Adjusted Gene Name Cortex Medulla Fold PBTs 
1.85E-11 6.2E-07 NPHS2 nephrosis 2, idiopathic, steroid-resistant (podocin) 1221 43 28.62 KT1 
2.62E-11 6.2E-07 FGF1 fibroblast growth factor 1 (acidic) 470 95 4.95 KT1 
3.76E-11 6.2E-07 ST6GALNAC3 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N- 50 26 1.9 
 
9.4E-11 1.16E-06 FGF1 fibroblast growth factor 1 (acidic) 69 40 1.72 KT1 
2.87E-10 2.4E-06 NPHS1 nephrosis 1, congenital, Finnish type (nephrin) 106 22 4.9 
 
2.9E-10 2.4E-06 ZDHHC14 zinc finger, DHHC-type containing 14 131 217 0.6 
 
4.7E-10 2.93E-06 NTNG1 netrin G1 52 21 2.47 
 
4.93E-10 2.93E-06 KLK7 kallikrein-related peptidase 7 115 47 2.43 HT1 
5.33E-10 2.93E-06 KLK6 kallikrein-related peptidase 6 100 40 2.47 
 
6.18E-10 3.06E-06 CLIC5 chloride intracellular channel 5 95 28 3.35 
 
7.13E-10 3.21E-06 PTPRO protein tyrosine phosphatase, receptor type, O 246 79 3.1 
 
8.27E-10 3.41E-06 MME membrane metallo-endopeptidase 275 51 5.42 KT1 
1.18E-09 3.96E-06 PLA2R1 phospholipase A2 receptor 1, 180kDa 226 106 2.14 
 
1.28E-09 3.96E-06 PLCE1 phospholipase C, epsilon 1 101 40 2.5 
 
1.28E-09 3.96E-06 PTPRO protein tyrosine phosphatase, receptor type, O 95 33 2.85 
 
1.29E-09 3.96E-06 CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5 135 27 5.09 
 
1.41E-09 3.96E-06 CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5 307 79 3.9 
 
1.44E-09 3.96E-06 NOX4 NADPH oxidase 4 587 78 7.48 ENDAT 
1.71E-09 4.24E-06 CLIC5 chloride intracellular channel 5 899 146 6.16 
 
1.71E-09 4.24E-06 TNNT2 troponin T type 2 (cardiac) 81 24 3.34 
 
1.83E-09 4.3E-06 PTPRO protein tyrosine phosphatase, receptor type, O 296 57 5.2 
 
2.01E-09 4.3E-06 NOX4 NADPH oxidase 4 979 130 7.54 ENDAT 
2.02E-09 4.3E-06 PLCXD3 phosphatidylinositol-specific phospholipase C, X domain containing 3 181 61 2.97 HT1 
2.09E-09 4.3E-06 PODXL podocalyxin-like 2064 884 2.33 ENDAT 
2.43E-09 4.73E-06 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 378 102 3.72 KT1 
2.48E-09 4.73E-06 NOX4 NADPH oxidase 4 1193 162 7.35 ENDAT 
2.78E-09 5.1E-06 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 303 75 4.06 KT1 
2.89E-09 5.11E-06 NOX4 NADPH oxidase 4 1588 221 7.18 ENDAT 
3.23E-09 5.16E-06 NTNG1 netrin G1 43 18 2.38 
 
3.23E-09 5.16E-06 REN renin 389 38 10.2 KT1 
PBTs - pathogenesis based transcript sets; KT1 - kidney transcripts; ENDAT - endothelial transcripts; fdr - false discovery rate. Au
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Table 3. Chi square test statistical values for Figures 6 (A-I) and 7 (A-C)* 
Figure # Description 
Distribution of molecular scores in quadrants 
Top right 
quadrant 
(C+M+) 
Top left 
quadrant 
(C+M-) 
Bottom right 
quadrant 
(C-M+) 
Bottom left 
quadrant 
(C-M-) 
P value 
Figure 6A ABMR – Biological replicates 25 39 5 5 0.51 
Figure 6B ABMR – Cortex/Medulla 9 25 11 11 0.07 
Figure 6C ABMR – Reference Set 354 745 30 61 0.88 
Figure 6D TCMR – Biological replicates 13 51 2 8 0.98 
Figure 6E TCMR – Cortex/Medulla 4 30 5 17 0.28 
Figure 6F TCMR – Reference Set 166 933 6 85 0.03 
Figure 6G Rejection – Biological replicates 39 25 7 3 0.58 
Figure 6H Rejection – Cortex/Medulla 10 24 12 10 0.06 
Figure 6I Rejection – Reference Set 534 565 38 53 0.21 
Figure 7A IRRATs – Cortex/Medulla 21 13 14 8 0.89 
Figure 7B IRRATs – Biological replicates 39 25 6 4 0.96 
Figure 7C IRRATs – Reference Set 456 643 37 54 0.88 
* The cutoffs in figure 1 divide the data into high cortex (“C+”) vs. low cortex (“C-“) and molecular score positive (“M+”) or 
negative (“M-“),  giving four quadrants: C+M+, C+M-, C-M+, and C-M-. 
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Table 4. Consistency in Diagnosis between Paired Samples 
Agreement* in Diagnosis between signed-out Biological Replicate MMDx reports (N=38 pairs) 
Number of Biological 
Replicate pairs 
Agreement/Disagreement Description 
32 Agreement* Comparable diagnosis with no substantive change 
4 Disagreement** Disagreement on a major diagnostic point (i.e. ‘No TCMR’ vs. ‘TCMR’) 
1 Ambiguous*** 
One or both reports ambiguous in ABMR or TCMR, so agreement could not 
be measured 
Agreement* in Diagnosis between signed-out Cortex and Medulla MMDx reports (N=26 pairs) (excluding 3 unpaired samples) 
Number of 
cortex/medulla pairs 
Agreement/Disagreement Description 
23 Agreement* Comparable diagnosis with no substantive change 
3 Disagreement** Disagreement on a major diagnostic point (i.e. ‘No TCMR’ vs. ‘TCMR’) 
* Agreement defined as either perfect agreement (presence/absence of type of rejection and agreement in scale, i.e. ‘Severe ABMR, No 
TCMR’ in both diagnostic signouts), or agreement on presence/absence of rejection with difference in scale (i.e. ‘Severe ABMR, No 
TCMR’ and ‘Moderate ABMR, no TCMR’). 
** Disagreement defined as a pair of samples with one having rejection and the other lacking rejection (i.e. ‘No ABMR, Moderate TCMR’ 
and ‘Moderate ABMR, Moderate TCMR’). 
*** Ambiguous samples included those with histological screen failures, ambiguous histology and molecular reads, or samples too 
damaged/lacking in quality for a proper diagnostic read. Agreement could not be determined in these cases as no distinct diagnostic 
prediction was possible. 
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